Abivax (CHIX:ABVXP) Other Operating Expense: €0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:ABVXP Abivax SA CHIX:ABVXP
28 GF Score
Price €89.93
! 1 Warning Sign
View Full Analysis

What is Abivax Other Operating Expense?

Abivax CHIX:ABVXP 28 Other Operating Expense is €0.00 Mil as of Mar. 2026. GuruFocus rates CHIX:ABVXP with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Abivax's Other Operating Expense for the three months ended in Mar. 2026 was €0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Abivax's annual Other Operating Expense declined from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) but then stayed the same from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€0.00 Mil).

Abivax Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Abivax's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abivax Other Operating Expense Chart

Abivax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.00 0.00 0.00 0.00

Abivax Quarterly Data
Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense 0.00 0.00 0.00 0.00 0.00
CHIX:ABVXP
28GF Score
Abivax SA CHIX:ABVXP
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abivax Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of €0.00 Mil mean?
Abivax (CHIX:ABVXP) has a Other Operating Expense of €0.00 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Abivax and its competitors.
Is Abivax's Other Operating Expense too high?
Abivax's current Other Operating Expense is €0.00 Mil. Overall, Abivax has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Abivax's Other Operating Expense compare to VRTX and REGN?
Abivax's Other Operating Expense of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Abivax and its competitors. Abivax's current Other Operating Expense is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abivax stock overvalued right now?
Abivax (CHIX:ABVXP) has a current Other Operating Expense of €0.00 Mil. The current Other Operating Expense is €0.00 Mil. Abivax's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Abivax (CHIX:ABVXP), the current Other Operating Expense is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Abivax Business Description

Address 7-11 boulevard Haussmann, Paris, FRA, 75009
Abivax SA is a French clinical-stage biotechnology company developing therapies that modulate the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate, obefazimod, is an orally administered small molecule being evaluated in Phase 3 clinical trials for adults with moderately to severely active ulcerative colitis, with the company also exploring its potential in other inflammatory bowel diseases such as Crohn's disease and in additional inflammatory conditions. Abivax operates as a single research and development segment, conducting its activities primarily in France with clinical trials across multiple countries. As a clinical-stage company, it has no approved products and generates no product revenue, funding its operations through equity financings, public offerings, and partnerships rather than commercial sales.
28GF Score

Get the complete analysis for CHIX:ABVXP

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€89.93
Price